What Happens If Perseris Is Injected Into a Muscle Instead of Subcutaneously?
Perseris (risperidone extended-release injectable suspension) must be injected subcutaneously into the abdomen for proper drug release via its ATRIGEL delivery system. Injecting it intramuscularly (IM) instead disrupts this mechanism, leading to altered pharmacokinetics and unreliable dosing.[1]
The prescribing information explicitly warns against IM injection: "PERSERIS is for subcutaneous use only. Do not administer PERSERIS intravenously or intramuscularly."[1] No clinical data exists on IM administration, but the formulation's polymer-based microsphere depot is optimized for subcutaneous tissue, where it forms a consistent depot for gradual risperidone release over one month.
Why Does the Route of Administration Matter for Perseris?
Perseris uses a biodegradable copolymer that hydrates and erodes slowly in subcutaneous fat, providing steady plasma levels (peak around day 10-11, therapeutic through day 28).[1][2] Muscle tissue has higher vascularity and different enzymatic activity, potentially causing:
- Faster initial release (risk of supratherapeutic levels and acute side effects like sedation or extrapyramidal symptoms).
- Incomplete or erratic absorption, leading to subtherapeutic levels and breakthrough psychosis.
Animal studies on similar ATRIGEL systems show route-dependent release profiles, supporting this risk.[3]
What Does the FDA Label Say About Improper Injection?
The label states: "Injection into the deltoid muscle or other intramuscular sites is not recommended and may result in more rapid release of risperidone."[1] While not explicitly tested in humans, this implies heightened toxicity risks without proven efficacy loss—clinicians should monitor closely or consider switching to oral risperidone if inadvertent IM injection occurs.
Reported Errors or Case Outcomes
No public case reports detail IM Perseris outcomes, likely due to rarity and underreporting. Similar long-acting injectables (e.g., other risperidone formulations like Risperdal Consta) show IM errors cause peak plasma spikes 2-3x higher than intended, per pharmacokinetic modeling.[4] For Perseris, healthcare providers report training to prevent this, with ultrasound guidance sometimes used for obese patients.[2]
What Should You Do If IM Injection Happens?
Contact the prescriber immediately for plasma level monitoring, symptom assessment, and potential dose adjustment. Avoid redosing until levels stabilize. Patient counseling emphasizes self-administration training to minimize errors.[1]
How Does Perseris Differ from Other Risperidone Injectables?
| Formulation | Route | Release Profile | IM Risk |
|-------------|--------|-----------------|---------|
| Perseris | Subcutaneous only | 1-month, ATRIGEL depot | Explicitly contraindicated; erratic release[1] |
| Risperdal Consta | IM (deltoid/gluteal) | 2-week microspheres | Standard route; no subQ alternative[5] |
| Rykindo | IM | 2-week/4-week | IM-specific; subQ unstudied[6] |
Perseris's subQ design reduces injection pain but demands strict adherence.[2]
Sources
[1]: Perseris Prescribing Information (Indivior, 2023)
[2]: FDA Approval Summary for Perseris
[3]: ATRIGEL Technology Overview (Janssen/Indivior)
[4]: Pharmacokinetic Study on LAI Risperidone Errors (Clin Pharmacokinet, 2019) – PubMed
[5]: Risperdal Consta PI (Janssen)
[6]: Rykindo PI (Yuneau Therapeutics, 2023)